人参皂甙Rg3与化疗联合治疗晚期乳腺癌的临床观察

Clincial study on the efficacy of Ginsensode Rg3 combined with chemotherapy in treatment of breast cancer patients at advanced stage

目的研究人参皂甙Rg3与化疗联合治疗晚期乳腺癌的疗效及安全性。方法治疗失败晚期乳腺癌患者40例,化疗方案均未紫杉醇+卡铂/顺铂,至少化疗2～3个周期,其中紫杉醇的剂量为135-175mg/m2,卡铂按Auc5计算,顺铂按50 mg/m2一次给药或分次给药,同时口服参一胶囊,用法为每日2次,每次20mg,56d为一疗程,口服2疗程以上。结果治疗组获益为90%,与对照组相比,效果显著,差异有统计学意义(P<0.01)。治疗组中恶心、呕吐及白细胞下降,均明显好于对照组,且P<0.05,具有统计学意义。结论人参皂甙Rg3与化疗联合治疗晚期乳腺癌了提高疗效,且降低化疗毒性反应。

Objective To explore the efficacy and safety of ginsenoside Rg3 combined with chemotherpy in treatment of breast cancer at advanced stage.Methods Eight breat cancer patiens were randomly divided into treatment group and control group each consisted of 40 cases.Forty breast cancer patients at advanced stage in the cotnrol group were treated with chemotherapy including paclitaxel with dose of 135-175mg/m2＋carboplatin/sis-platinum with dose of 50 mg/m2for at least 2~3 courses.Those in the treatment group were treated with the same regimen as that used in the control group in addition to oraly adminstration of a panaxoside capsule,twice a day,20mg per time and 56 days as a course for two courses.Results The excellent rate,stable rate and benefit rate of patients in treatment group were 50.0（20/40）、40.0（16/40）and 90.0（36/40） and that in the control group were 32.5（13/40）、37.5（15/40）、70.0（28/40）,showing significant differences between the groups（P0.01）.The adverse reactions rate in the treatment ggroup was lower than that in the control group,also showing significant differences（P0.05）.Conclusion Panaxoside incombination with chemotherapy can enhance the efficacy in treatment of breast cancer patients with low adverse reactions.